Probiotics

PROBIOTICS: PHARMACEUTICAL-QUALITY INNOVATIVE SOLUTIONS

The use of probiotics is a very promising alternative for the prevention and/or treatment of multiple health issues, in both humans and animals.

By modifying the composition of the microbiota with probiotics, we may help to mitigate and solve upper respiratory, genitourinary or gastrointestinal tracts and periodontal infections, as well as dysbiosis issues related to fertility, premature births, dermatology, autoimmune diseases, and many more. The key is to choose the appropriate strain and dosage for each therapeutic target.

A UNIQUE PROPOSAL

We took a pharmaceutical approach and decided to use Zendal’s Group knowledge of microbiology and microorganism management in order to develop and manufacture probiotics for human and animal health.

For that purpose, Zinereo completed in 2017 the construction of its new probiotic manufacturing facilities in Porriño, totally independent from the medicine manufacturing area.

In addition, after purchasing two Spanish companies specialized in probiotics through Zendal Group, Probisearch and Bialactis, it launched an ambitious preclinical, clinical, industrial and pharmaceutical development plan with the aim of organizing a portfolio of innovative probiotic products to address key health needs.

OUR ACCOMPLISHMENTS

As a result of this vision, the group has over 15 items available for commercialization and 8 clinical development lines of new products to be applied in upper respiratory infections, fertility issues, endometriosis, urinary tract infections, premature births, skin anti-aging and cell regeneration. Our products are available in more than 10 countries.

The highest pharmaceutical standards have been used for the clinical and industrial development and the manufacturing of the new Probiotics line, based on our more than 80 years of experience in the pharmaceutical industry and our commitment to customers, research, innovation, quality and the environment.